XTL Biopharmaceuticals Sign License Agreement with Yeda Research to Develop hCDR1 Treatment for SLE

by Charles Gross, Benzinga Editor
January 8, 2014 8:05 AM | 13 seconds read |
XTL Biopharmaceuticals XTLB today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus (SLE). See full press release
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsGuidanceContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!